| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6222025 | KASTLE THERAPS LLC | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
Mar, 2015
(9 years ago) | |
| US5914396 | KASTLE THERAPS LLC | 2'-O-modified nucleosides and phosphoramidites |
Jun, 2016
(7 years ago) | |
| US6451991 | KASTLE THERAPS LLC | Sugar-modified gapped oligonucleotides |
Feb, 2017
(7 years ago) | |
| US6166197 | KASTLE THERAPS LLC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(6 years ago) | |
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
| US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7407943 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Aug, 2021
(2 years ago) | |
Kynamro is owned by Kastle Theraps Llc.
Kynamro contains Mipomersen Sodium.
Kynamro has a total of 8 drug patents out of which 7 drug patents have expired.
Expired drug patents of Kynamro are:
- US7407943
- US6222025
- US5914396
- US6451991
- US6166197
- US7015315
- US7101993
Kynamro was authorised for market use on 29 January, 2013.
Kynamro is available in solution;subcutaneous dosage forms.
Kynamro can be used as adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with homozygous familial hypercholesterolemia.
Drug patent challenges can be filed against Kynamro from 29 January, 2017.
The generics of Kynamro are possible to be released after 29 January, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-41) | Jan 29, 2020 |
| Orphan Drug Exclusivity(ODE) | Jan 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 29, 2018 |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
NCE-1 date: 29 January, 2017
Market Authorisation Date: 29 January, 2013
Treatment: Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with h...
Dosage: SOLUTION;SUBCUTANEOUS
KYNAMRO family patents
